Research Title: A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Variants of Complement Factor H (CFH)
Sponsor: Gemini Therapeutics, Inc.
Principal Investigator: Robert Stoltz, M.D., Ph.D.
Description: This is a prospective, multicenter, natural history (NH) study, conducted in subjects with non-central GA secondary to dry age-related macular degeneration (AMD). There will be 2 cohorts of subjects with non-central GA. The first cohort will be those who have tested positive for rare CFH variants and associated complotypes, and will total 125 subjects; the second cohort of 100 subjects will be homozygous CFH risk genotype Y402H;Y402H. The study is designed to better characterize the relationship between genotype, visual function, and progression of AMD by functional and structural ocular endpoints. The study is intended to generate new information on the relationship between genetics and AMD progression.
Start Date: June 2019
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CCRC, COA; Stephanie Campbell, CRC, COA; Amber Adams, CRC, COA
Location(s): Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060